38 studies 89 arms 3923 patients ▪ lack of control group unless

Slides:



Advertisements
Similar presentations
In the name of GOD In the name of GOD.
Advertisements

The Biggest Loser Challenge: A Pill for Atypical Antipsychotic Induced-Weight Gain? Julie A. Dopheide, Pharm.D., BCPP Associate Professor of Clinical Pharmacy,
Intro to Psychopharmacology Caitlin Stork, MD. Besides dopamine blockade... ReceptorEffect of Blockade Acetylcholine (muscarinic; M1) Anticholinergic.
Pharmaceutical Approaches to Stuttering Jennifer VanHulle Justine Siepmann Kristin Scheunemann.
Agency for Healthcare Research and Quality (AHRQ)
Statins In COPD: A Systematic Review Surinder J, Kirly P et al. Chest 2009; 136: Divya Bappanad March 11, 2010 Journal Club.
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder:
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia: Efficacy and Safety Outcomes of the CATIE Trial Ira D. Glick, MD Stanford.
The Clinical Antipsychotic Trials of Intervention Effectiveness Trial
Health Behavior Change With attribution to Steve Bartels, MD – Dartmouth and the SAMHSA/HRSA Center for Integrated Health Solutions.
Increase the Proportion of Metabolic Syndrome Screening In Adults with Severe Mental Illness receiving "atypical” second generation antipsychotics.
1 Evidence Model for Treatment of Overweight and Obesity Cardiovascular Disease Cardiovascular Mortality and Morbidity Noncardiovascular Mortality and.
OPTIMAL TREATMENT INTERVENTIONS IN RECENT-ONCET PSYCHOSIS Vassilis P. Kontaxakis Associate Professor of Psychiatry, University of Athens.
A meta-analysis, of the efficacy of second generation antipsychotics (SGAs) 142 controlled studies were reviewed 124 studies of SGAs vs FGA, patients.
Cardiometabolic Consequences of Risperidone in Children with Autism Cardiometabolic Consequences of Risperidone in Children with Autism Susan J. Boorin,
Use of Atypical Antipsychotic Drugs by Children and Adolescents in the United States: A Retrospective Cohort Study Lesley H. Curtis, PhD Center for Clinical.
Using Recent Research to Improve the Cost-Effectiveness of VA Antipsychotic Formulary Policy Robert Rosenheck MD Michael Sernyak MD New England MIRECC.
Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents Sandhya Mehta, MS; Hua Chen, MD, PhD; Michael Johnson, PhD; and Rajender R. Aparasu,
Pharmacotherapy in Psychotic Disorders. Antipsychotic drugs Treat the symptoms of the disorder Do not cure schizophrenia Include two major classes: –
WHAT IS THE EVIDENCE ON EFFECTIVENESS OF ANTIPSYCHOTICS IN PERSONS WITH DEMENTIA? 1.
Treatment of Schizophrenia THE DEBATE OF THE YEAR! EFFICACY vs. TOLERABILITY: WHICH TRUMPS? POINT- COUNTERPOINT.
© 2004, Wellsource Inc. Low Carbohydrate Diet and LDL Cholesterol Levels 119 men and women, 24 weeks On the low carb diet, LDL increased slightly On low.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
MIAMI: MIRECC Initiative on Antipsychotic Management Improvement Metabolic Monitoring and Management of Antipsychotic Medication.
Teresa Hudson, PharmD Center for Mental Healthcare and Outcomes Research South Central Mental Illness Research Education and Clinical Center.
Changes in Antipsychotic Pharmacotherapy and Healthcare Costs Following a New Diagnosis of Diabetes among Patients with Schizophrenia Douglas L. Leslie,
Prescribing in Dementia. Plan What to prescribe? When to prescribe? How to review? Who to review?
CATIE STUDY Clinical Antipsychotic Trials of Intervention Effectiveness Effectiveness of Antipsychotic Drugs in patients with Chronic Schizophrenia – Lieberman.
for MHD & Therapeutics is proud to present And Now Here Is The Host... Dr. Schilling.
Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:
Treatment for Early onset Schizophrenia Treatment for Early onset Schizophrenia Chia-Yi Christian Hospital Department of psychiatry Hou, Yuh-Ming M.D.
 In 2003, the USPSTF recommended that clinicians screen adults for obesity and offer intensive counseling and behavioral interventions to promote weight.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aripiprazole, an Antipsychotic With a Novel Mechanism.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparative Mortality Risk in Adult Patients With.
Prescribing antipsychotics for children and adolescents
Module 3 Use of antipsychotics for unipolar depression
Module 3 Indications for Antipsychotics Bipolar Disorder
Treatment with rosuvastatin for severe dyslipidaemia in patients with schizophrenia and schizoaffective disorder M De Hert1, D Kalnicka1, R van Winkel1,
Almost all antipsychotics result in weight gain. Meta-analysis
One-Year Weight Gain While on Treatment with an Antipsychotic
Antipsychotic Prescribing
Antipsychotics academic detailing
Copyright © 2005 American Medical Association. All rights reserved.
Schizophrenia’s Heterogeneity
HbA1c 1245_0025final study-report-body. Table : 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD)
Quality improvement programme
End point Rimonabant 20 mg (n=339) Placebo (n=348) p Weight (kg) -5.3
Antipsychotics and Diabetes
Antipsychotic Agents and Their Use in Schizophrenia
Bipolar Depression Pharmacotherapy: Part 1
Pharmacodynamics: How do antipsychotic medications work?
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Antipsychotics: chemistry and pharmacokinetics
Lurasidone Flavio Guzmán, MD.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Dual SGLT1/SGLT2 Inhibition in T1D
Antipsychotics: The Essentials Module 4 Metabolic & Other Adverse Effects Flavio Guzmán, MD.
Risperidone – Binding Profile
Dr James Ovens Consultant Psychiatrist Tandridge CMHRS
Drug (Study) Sample (# with GAD) Mean Dose Length (Wks) HAM-A
Full citations found in PubMed database
Topic Discussion By Alexandria Brown
379 failed screeninga 120 failed run inb
Dan McGraw, PharmD, BCPP Clinical Pharmacy Specialist in Psychiatry
Benefit and risk of intrathecal morphine without local anaesthetic in patients undergoing major surgery: meta-analysis of randomized trials  N. Meylan,
Presentation transcript:

38 studies 89 arms 3923 patients ▪ lack of control group unless Potentially relevant CTs identified and screened for retrieval (N=115) RCTs included in the analysis Short term CTs: duration ≤12 weeks (N=38) Potentially appropriate RCTs to be Included in the analysis (N=64) RCTs excluded because of: ▪ design (crossover, combination, retrospective, discontinuation) (N=8) ▪ lack of control group unless duration ≥ 13 weeks (N=26) ▪ other interests (young adults, pharmaco/vigilance or kinetics (N=9) ▪ Review or meta-analysis (N=6) ▪ Arm with N < 9 (N=2) RCTs excluded from analysis because of data reported elsewhere (N=9) Long term CTs: duration ≥13 weeks (N=16) 38 studies 89 arms 3923 patients Incomplete reporting of all variables of interest (N=1)

Weight gain : compared to placebo 29 studies 65 arms - 3204 patients Weight gain : compared to placebo kg Arm (N) Patient (N) 4 228 61 8 606 7 413 10 351 16 691 16 854 Placebo

Patients with significant weight gain 24 studies 57 arms - 3229 patients Patients with significant weight gain Arm (N) Patient (N) 3 212 57 8 612 5 345 297 15 759 15 947 Placebo

12 studies 32 arms - 1511 patients Arm (N) Patient (N) 1 12 8 606 3 68 324 5 131 7 370 Placebo

10 studies 27 arms - 1784 patients mg/dl Arm (N) Patient (N) 3 212 243 5 371 4 259 187 8 512 Placebo

10 studies 27 arms - 1784 patients mg/dl Arm (N) Patient (N) 3 212 243 5 371 4 259 187 8 512 Placebo

10 studies 27 arms - 1655 patients mg/dl Arm (N) Patient (N) 3 212 243 6 388 152 4 187 8 473 Placebo

somnolence/sedation : compared to placebo 29 studies 64 arms - 3305 patients somnolence/sedation : compared to placebo Arm (N) Patient (N) 7 228 1 12 8 612 404 254 17 775 19 1020 Placebo

26 studies 61 arms - 3209 patients Arm (N) Patient (N) 3 212 8 612 6 362 109 21 938 17 976 Placebo

Risperidone Olanzapine Quetiapine Aripiprazole Clozapine Ziprasidone  Weight ++ ++++ +++ +  Glucose +/- ?  Cholesterol  Trigly  Prolactin Somnolence Extra-pyramidal 0?